Antimicrobial Resistance and Infection Control 2014,3 :31
A compendium of TB REACH case studies, lessons learned and a monitoring and evaluation framework.
Accessed November 2017.
Monitoring of implementation of collaborative TB/HIV activities and evaluation of impact is critically important. This requires efficient monitoring and evaluation system so as to establish accountability mechanisms between programmes, the population they serve, and donors. The Guide to monitoring a...nd evaluation for collaborative TB/HIV activities will facilitate this process. The first version of the guide was developed in 2004 placing collaborative TB/HIV activities as integral part of national TB/HIV response. It was revised in 2009 to harmonize the approaches and indicators for monitoring and evaluation across key stakeholders. The current revision builds upon remarkable progress in implementation of collaborative TB/HIV activities and aims to strengthen the implementation further through improved quality of data.
more
Q8: What is the effectiveness, safety and role of pharmacological interventions, by non-specialized health care providers, for the broad category of Disruptive Behaviour Disorders (DBDs), Conduct Disorder (CD), Oppositional Defiant Disorder (ODD) and comorbid (but not exclusively) Attention-Deficit ...Hyperactivity Disorder (ADHD)?
more
The right to the enjoyment of the highest attainable standard of physical and mental health is enshrined in many international human rights treaties. However, studies have shown that people with mental disabilities are often marginalized and discriminated against in the fulfillment of their right to... health. The aim of this study is to identify and reach a broader understanding of barriers to the right to mental health in the Eastern Cape Province in South Africa. Eleven semi-structured interviews were carried out with health professionals and administrators.
more
A survival guide for clinicans.
3rd edition.
WHO/HTM/HIV/2007.01 WHO/HTM/TB/2007.380
5th revised edition.
This document provides a ranking of medically important antimicrobials for risk management of antimicrobial resistance due to non-human use. The current revision took place at the seventh meeting of the AGISAR held in Raleigh, United States of America in 2016.
Statutory Instrument 150 of 1991 | S.I. 150 of 1991 | Amended by S.I.’ s 298/93, 61/94, 319/94, 199/98, 256/98, 36/99, 24/2001 and 257/2002, 105 and 222 /2004